A combination of antihypertensive, antithrombotic, and/or lipid modifying drugs after a recent noncardioembolic stroke is associated with a significantly lower risk of stroke, major vascular events, and death, the analysis of an international multicenter trial involving 3,680 recent noncardioembolic stroke patients revealed. Patients (>= 35 years old) were categorized by appropriateness level 0 to III depending on the number of drugs prescribed divided by the number of drugs potentially indicated for each patient and followed for 2 years. A significant protective effect of the triple class therapy was seen on stroke (0.37, 95% CI 0.16-0.90), major vascular events (0.34, 95% CI 0.18–0.62), and all-cause death (0.25, 95% CI 0.0-0.74). The drug combination should be considered as an integral part of a comprehensive recurrent stroke prevention strategy that includes efforts to reduce smoking, increase physical activity, and control diet. Source: http://www.neurology.org/对一项包括近3680名非心源性脑栓塞患者的国际性多中心临床试验的分析显示，近期非心源性脑栓塞后降压，抗血栓形成，和/或调脂药物的组合与中风，主要血管 事件和死亡风险的显著降低有关。对每个患者（>=35岁）根据处方药的数量与有用药指征的药物数量之比进行了0~三级适当归类并随访2年。观察到该三联疗法对中风（0.37，95％CI 0.16-0.90），主要血管事件（0.34，95％CI 0.18-0.62），以及全因死亡（0.25，95％CI 0.0 -0.74）有显著的保护作用。该药物联合应作为一个综合的复发性中风预防策略的一部分，其中包括努力减少吸烟，加强体育活动和控制饮食。来源：http://www.neurology.org/
This website uses cookies.